Virtuele bijeenkomst ESMO highlights

Dag: 22 september

Tijdstip: 18.30-20.00 uur

Expert panel bediscussieert onderstaande ESMO sessies en de implicaties voor de dagelijkse Nederlandse Praktijk.

[Proffered Paper 1 - GU, non prostate](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/220)

Date

19.09.2020

Time

16:20 - 18:00

Room

Channel 3

Chairs

* Richard Cathomas (Chur, Switzerland)

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/1572)

LBA23 - Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361

Presentation Number

LBA23

Lecture Time

16:20 - 16:32

Speakers

* Ajjai Alva (Ann Arbor, MI, United States of America)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/220)

Room

Channel 3

Date

19.09.2020

Time

16:20 - 18:00

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/881)

697O - A phase 3, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)

Presentation Number

697O

Lecture Time

16:32 - 16:44

Speakers

* Thomas B. Powles (London, United Kingdom)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/220)

Room

Channel 3

Date

19.09.2020

Time

16:20 - 18:00

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/4868)

Invited Discussant LBA23 and 697O

Lecture Time

16:44 - 16:54

Speakers

* Richard Cathomas (Chur, Switzerland)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/220)

Room

Channel 3

Date

19.09.2020

Time

16:20 - 18:00

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/5099)

Q&A live discussion

Lecture Time

16:54 - 17:04

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/220)

Room

Channel 3

Date

19.09.2020

Time

16:20 - 18:00

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/1189)

LBA24 - TROPHY-U-01 Cohort 1 Final Results: A Phase 2 Study of Sacituzumab Govitecan (SG) in Metastatic Urothelial Cancer (mUC) That Has Progressed After Platinum (PLT) and Checkpoint Inhibitors (CPI)

Presentation Number

LBA24

Lecture Time

17:04 - 17:16

Speakers

* Yohann Loriot (Villejuif, France)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/220)

Room

Channel 3

Date

19.09.2020

Time

16:20 - 18:00

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/3740)

698O - Patient-reported outcomes (PROs) from IMvigor130: a global, randomised, partially blinded Phase III study of atezolizumab (atezo) + platinum-based chemotherapy (PBC) vs placebo (PBO) + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)

Presentation Number

698O

Lecture Time

17:16 - 17:28

Speakers

* Aristotelis Bamias (Athens, Attiki, Greece)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/220)

Room

Channel 3

Date

19.09.2020

Time

16:20 - 18:00

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/2214)

699O - Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): association between clinical outcomes and exploratory biomarkers

Presentation Number

699O

Lecture Time

17:28 - 17:40

Speakers

* Srikala Sridhar (Toronto, ON, Canada)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/220)

Room

Channel 3

Date

19.09.2020

Time

16:20 - 18:00

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/4876)

Invited Discussant LBA24, 698O and 699O

Lecture Time

17:40 - 17:50

Speakers

* Jürgen Gschwend (Munich, Germany)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/220)

Room

Channel 3

Date

19.09.2020

Time

16:20 - 18:00

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/5100)

Q&A live discussion

Lecture Time

17:50 - 18:00

[Presidential Symposium II](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/240)

Date

20.09.2020

Time

18:30 - 20:25

Room

Channel 1

Chairs

* Solange Peters (Lausanne, Switzerland)

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/4277)

LBA3 - An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement. Primary end-point analysis of Lung ART (IFCT-0503, UK NCRI, SAKK) NCT00410683.

Presentation Number

LBA3

Lecture Time

18:30 - 18:42

Speakers

* Cécile Le Pechoux (Villejuif, CEDEX, France)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/240)

Room

Channel 1

Date

20.09.2020

Time

18:30 - 20:25

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/5572)

Invited Discussant LBA3

Lecture Time

18:42 - 18:52

Speakers

* Rafal Dziadziuszko (Gdansk, Poland)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/240)

Room

Channel 1

Date

20.09.2020

Time

18:30 - 20:25

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/5574)

Q&A live discussion

Lecture Time

18:52 - 19:02

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/240)

Room

Channel 1

Date

20.09.2020

Time

18:30 - 20:25

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/4308)

LBA4 - IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)

Presentation Number

LBA4

Lecture Time

19:02 - 19:14

Speakers

* Johann S. De Bono (London, United Kingdom)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/240)

Room

Channel 1

Date

20.09.2020

Time

18:30 - 20:25

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/2914)

610O - Final overall survival (OS) analysis of PROfound: olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

Presentation Number

610O

Lecture Time

19:14 - 19:26

Speakers

* Johann S. De Bono (London, United Kingdom)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/240)

Room

Channel 1

Date

20.09.2020

Time

18:30 - 20:25

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/5573)

Invited Discussant LBA4 and 610O

Lecture Time

19:26 - 19:36

Speakers

* Henrik Grönberg (Stockholm, Sweden)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/240)

Room

Channel 1

Date

20.09.2020

Time

18:30 - 20:25

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/5575)

Q&A live discussion

Lecture Time

19:36 - 19:51

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/240)

Room

Channel 1

Date

20.09.2020

Time

18:30 - 20:25

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/1052)

LBA5 - Abemaciclib in high risk early breast cancer

Presentation Number

LBA5

Lecture Time

19:51 - 20:03

Speakers

* Stephen R. Johnston (London, United Kingdom)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/240)

Room

Channel 1

Date

20.09.2020

Time

18:30 - 20:25

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/5601)

Invited Discussant LBA5

Lecture Time

20:03 - 20:13

Speakers

* George Sledge (Indianapolis, United States of America)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/240)

Room

Channel 1

Date

20.09.2020

Time

18:30 - 20:25

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/5602)

Q&A live discussion

Lecture Time

20:13 - 20:23

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/240)

Room

Channel 1

Date

20.09.2020

Time

18:30 - 20:25

Close Session Details

[Proffered Paper - GU, prostate](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/232)

Date

21.09.2020

Time

14:25 - 16:05

Room

Channel 1

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/2333)

609O - Results from a phase 1 study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)

Presentation Number

609O

Lecture Time

14:25 - 14:37

Speakers

* Ben Tran (Melbourne, Australia)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/232)

Room

Channel 1

Date

21.09.2020

Time

14:25 - 16:05

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/4848)

Invited Discussant 609O

Lecture Time

14:37 - 14:47

Speakers

* Cora N. Sternberg (New York, United States of America)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/232)

Room

Channel 1

Date

21.09.2020

Time

14:25 - 16:05

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/5124)

Q&A live discussion

Lecture Time

14:47 - 14:57

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/232)

Room

Channel 1

Date

21.09.2020

Time

14:25 - 16:05

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/2926)

611O - Abiraterone acetate plus prednisolone for hormone-naïve prostate cancer (PCa): long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476)

Presentation Number

611O

Lecture Time

14:57 - 15:09

Speakers

* Nicholas James (Birmingham, United Kingdom)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/232)

Room

Channel 1

Date

21.09.2020

Time

14:25 - 16:05

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/4852)

Invited Discussant 611O

Lecture Time

15:09 - 15:19

Speakers

* Maria De Santis (Berlin, Germany)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/232)

Room

Channel 1

Date

21.09.2020

Time

14:25 - 16:05

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/5125)

Q&A live discussion

Lecture Time

15:19 - 15:29

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/232)

Room

Channel 1

Date

21.09.2020

Time

14:25 - 16:05

Close Session Details

[Proffered Paper 2 - GU, non prostate](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/236)

Date

21.09.2020

Time

16:20 - 18:00

Room

Channel 2

Chairs

* Manuela Schmidinger (Vienna, Austria)
* Viktor Grünwald (Essen, Germany)

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/2762)

700O - Kidney ccRCC Immune Classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to Nivolumab (N)

Presentation Number

700O

Lecture Time

16:20 - 16:32

Speakers

* Maxime Meylan (Paris, France)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/236)

Room

Channel 2

Date

21.09.2020

Time

16:20 - 18:00

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/3651)

701O - Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing

Presentation Number

701O

Lecture Time

16:32 - 16:44

Speakers

* Zeynep B. Zengin (Duarte, United States of America)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/236)

Room

Channel 2

Date

21.09.2020

Time

16:20 - 18:00

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/4877)

Invited Discussant 700O and 701O

Lecture Time

16:44 - 16:54

Speakers

* Manuela Schmidinger (Vienna, Austria)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/236)

Room

Channel 2

Date

21.09.2020

Time

16:20 - 18:00

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/5132)

Q&A live discussion

Lecture Time

16:54 - 17:04

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/236)

Room

Channel 2

Date

21.09.2020

Time

16:20 - 18:00

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/3670)

702O - Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): results from the COSMIC-021 study

Presentation Number

702O

Lecture Time

17:04 - 17:16

Speakers

* Sumanta Pal (Duarte, United States of America)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/236)

Room

Channel 2

Date

21.09.2020

Time

16:20 - 18:00

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/2182)

LBA25 - Results from the phase 2 BIOmarker driven trial with Nivolumab (N) and Ipilimumab or VEGFR tyrosine Kinase inhibitor (TKI) in naïve metastatic Kidney cancer (m-ccRCC) patients (pts): the BIONIKK trial.

Presentation Number

LBA25

Lecture Time

17:16 - 17:28

Speakers

* Yann Vano (Paris, France)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/236)

Room

Channel 2

Date

21.09.2020

Time

16:20 - 18:00

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/4881)

Invited Discussant 702O and LBA25

Lecture Time

17:28 - 17:38

Speakers

* Laurence Albiges (Villejuif, France)

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/236)

Room

Channel 2

Date

21.09.2020

Time

16:20 - 18:00

**Proffered Paper session** **Proffered Paper session**

* [Calendar Export](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/icalc/presentation/5133)

Q&A live discussion

Lecture Time

17:38 - 17:48

Session Name

[Proffered Paper session](https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/show/session/236)

Room

Channel 2

Date

21.09.2020

Time

16:20 - 18:00

Close Session Details